Dr. Seidman on Ixabepilone in Patients With Aggressive Breast Cancer

Andrew D. Seidman, MD
Published: Friday, Mar 18, 2016



Andrew D. Seidman, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the label indication for ixabepilone (Ixempra) for the treatment of patients with aggressive breast cancer.

Ixabepilone represents the importance of having microtubule-binding agents available in the treatment paradigm of breast cancer, Seidman says. Earlier evidence of this was seen with therapies such as vincristine and vinblastine, as well as with the integration of taxanes.

Ixabepilone is approved as a single agent on an every 3-week schedule in patients whose disease is resistant to anthracyclines, taxanes, and capecitabine. In a large phase II study examining ixabepilone, the agent demonstrated a 12% response rate in patients and was associated with a significant median progression-free survival.

<<< View more from the 33rd Annual Miami Breast Cancer Conference



Andrew D. Seidman, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the label indication for ixabepilone (Ixempra) for the treatment of patients with aggressive breast cancer.

Ixabepilone represents the importance of having microtubule-binding agents available in the treatment paradigm of breast cancer, Seidman says. Earlier evidence of this was seen with therapies such as vincristine and vinblastine, as well as with the integration of taxanes.

Ixabepilone is approved as a single agent on an every 3-week schedule in patients whose disease is resistant to anthracyclines, taxanes, and capecitabine. In a large phase II study examining ixabepilone, the agent demonstrated a 12% response rate in patients and was associated with a significant median progression-free survival.

<<< View more from the 33rd Annual Miami Breast Cancer Conference




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x